NCT04403308View on ClinicalTrials.gov

ONO-7913 Phase I Study (ONO-7913)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 28, 2020

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions
Solid Tumor
Interventions
BIOLOGICAL

ONO-7913

ONO-7913 will be administered by intravenous continuous infusion during the designated time.

Trial Locations (1)

Unknown

Local Institution, Chuo-ku

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY